Resposta humoral associada a glicosilação no cancro do esófago by Fernandes, Elisabete Cristina Nunes
  
 
Universidade de Aveiro 
2012 
Departamento de Química 
Elisabete Cristina  
Nunes Fernandes 
 
Resposta humoral associada a glicosilação no cancro do 
esófago 
 
Humoral responses against esophageal  
cancer-associated glycosylation  
 
 
  
   
  
  
 
Universidade de Aveiro 
2012  
Departamento de Química 
Elisabete Cristina Nunes 
Fernandes 
 
 
Resposta humoral associada a glicosilação no cancro 
do esófago  
 
Humoral responses against esophageal cancer-
associated glycosylation 
 
 
 Dissertação apresentada à Universidade de Aveiro para cumprimento dos 
requisitos necessários à obtenção do grau de Mestre em Bioquímica 
Clínica, realizada sob a orientação científica do Professor José Alexandre 
Ferreira, Investigador de Pós-Doutoramento do Centro de Invesigação do 
Instituto de Oncologia do Porto (IPO- Porto) e do Departamento de 
Química da Universidade de Aveiro e Professor Doutor Lúcio Lara Santos 
do IPO-Porto 
 
  
   
  
  
  
  
 
dedicatória 
 
 
Dedico este trabalho a todos que o tornaram possível. 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
O júri  
Presidente Professora Doutora Rita Maria Pinhos Ferreira 
Professora auxiliar do Departamento de Química da Universidade de Aveiro 
 
 
Professor Doutor Celso Alburquerque Reis 
Professor no Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP). 
 
 
 Doutor José Alexandre Ribeiro de Castro Ferreira 
Investigador de Pós-Doutoramento do Centro de Investigação do Instituto de Oncologia do Porto 
(IPO- Porto) e do Departamento de Química da Universidade de Aveiro  
 
 
 Professor Doutor Lúcio Lara Santos 
Centro de Investigação do Instituto de Oncologia do Porto (IPO- Porto 
 
  
 
  
  
 
  
  
 
  
  
  
  
 
Agradecimento Este trabalho é o culminar de mais uma etapa para a qual contribuíram os 
conhecimentos adquiridos, tanto profissionais como pessoais ao longo dos anos. Assim 
sendo, cumpro assim o dever de agradecer às seguintes pessoas, pelo apoio prestado e 
que contribuíram de algum modo para a realização deste trabalho 
 
Ao Doutor José Alexandre Ferreira, pela orientação inigualável, pelo apoio que me 
permitiu desenvolver autonomia, pela confiança em mim depositada, por todos os 
conhecimentos transmitidos, pela alegria e incentivo quando o desânimo era a atitude 
mais fácil. Um muito obrigado por tudo… 
 
Ao Mestre Luís Lima, por todo o apoio laboratorial e conhecimento transmitido, bem 
como, pela simpatia com que me recebeu no grupo de Patologia e Terapêutica 
Experimental. 
 
Ao Professor Doutor Lúcio Lara Santos por me ter recebido no grupo de Patologia e 
Terapêutica Experimental do Instituto Português de Oncologia do Porto (IPO-Porto). 
 
Ao Professor Doutor Celso Reis, um obrigado pelo fornecimento dos anticorpos e de 
todo o apoio prestado. 
 
À distinta mestre Andreia Miranda por ter estado sempre sempre ao meu lado ao logo 
destes cinco anos até nesta última etapa, pela ajuda na realização do trabalho mas 
principalmente pela amizade, e pelos momentos memoráveis que guardo. Contigo a 
meu lado foi sempre tudo mais fácil. 
 
Às minhas colegas de laboratório Daniela Oliveira e Ana Margarida Gonçalves pela 
ajuda durante a realização deste trabalho mas mais que isso, um obrigada pela amizade, 
pela alegria, pelo apoio e pelo bom humor contagiante que vos assiste.  
 
Ao Paulo Branco e aos meus pais por toda a compreensão, por todo apoio incondicional 
que sempre me transmitem, pela confiança e pelo ânimo transmitido quando os dias não 
corriam tão bem. 
 
A todos os meus restantes amigos e companheiros de curso sem excepções um obrigada 
pela vossa amizade, carinho e alegria. 
 
 
 
 
 
E as todos aqueles que de alguma forma contribuíram para que este trabalho fosse 
possível um muito Obrigada! 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
palavras-chave 
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Resumo 
 
 
O cancro de esófago (CE) tem um mau prognóstico e uma baixa taxa de sobrevivência. 
É diagnosticado tardiamente, por endoscopia, um método invasivo que carece de 
especificidade e sensibilidade. Atualmente, não existem biomarcadores para melhorar a 
precisão do diagnóstico. 
A transformação maligna é acompanhada por alterações no padrão de glicosilação das 
células, que são utilizadas no diagnóstico não-invasivo, monitorização da doença, bem 
como terapêutica. Além disso, as proteínas exibindo glicosilação alterada são capazes 
de induzir respostas humorais. Os auto-anticorpos são uma nova geração de 
biomarcadores tumorais, com capacidade de amplificar alterações moleculares nos 
tumores. São ainda mais resistentes a proteólise o que os correspondentes epitopos. No 
entanto, pouco se sabe sobre a glicosilação em CE e a sua imunogenicidade. 
Assim, a primeira parte deste trabalho teve como objetivo identificar padrões de 
glicosilação no soro de doentes com CE por slot blotting. Foram considerados para este 
estudo os cinco antigénios tumorais Tn, sTn, T, sLe
a
, e sLe
x
. Verificou-se que os níveis 
de Tn, sTn, e do sLe
a
 estavam aumentados no soro de pacientes com EC, em 
comparação com um grupo de controlo, comparável em idade e género, sem doença 
maligna conhecida. A combinação dos antígenos Tn e sTn permitiu uma melhor 
discriminação entre CE e os controlos (sensibilidade de 93,8% e especificidade de 
100%). A expressão destes antigénios nos tecidos de CE correspondentes, estimada por 
imuno-histoquímica, mostrou uma falta de correlação com as observações feitas no 
soro. Os dados sugerem que os padrões de glicosilação do soro são maioritariamente 
influenciados por proteínas não directamente secretadas ou libertadas por células 
tumorais, apesar de a sua contribuição não poder ser excluída. 
A segunda parte do trabalho visou identificar respostas humorais contra proteínas que 
transportam o sLe
a
, um biomarcador associado à glicosilação com maior potencial de 
migração celular e metástase. A análise do perfil de IgG das amostras apresentou uma 
expressão aumentada de uma subclasse (IgG1) nos doentes com CE. As IgG1 
produzidas de novo por indução tumoral demonstraram possuir sLe
a
 na sua estrutura, 
contribuindo assim para o aumento dos níveis deste antigénio no soro de doentes com 
EC. Ainda que os mecanismos biológicos por detrás deste evento não sejam ainda 
conhecidos, isso poderá permitir melhorar a sensibilidade e especificidade do teste 
sorológico de sLe
a
 (teste de CA19-9). Usando uma combinação de técnicas de 
immunoprecipiações e de Western blotting, foi ainda demonstrado, pela primeira vez, 
que as proteínas tumorais que transportam sLe
a
 podem induzir a produção de IgG1. A 
remoção do ácido siálico confirmou que a expressão de sLe
a
 era determinante para o 
reconhecimento de IgG1. Estas observações, bem como a identificação futura de 
proteínas imunogénicas transportadoras de sLe
a
, prmitirão determinar o seu valor 
clínico e poderão ser um ponto de partida para o desenvolvimento de testes serológicos 
baseados em autoanticorpos.  
Em suma, eviências importantes foram encontradas com este estudo, que permitirão o 
desenvolvimento de testes serológicos não invasivos para a detecção de CE 
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abstract 
 
Esophageal cancer (EC) has an extremely poor prognosis and decreased 
overall survival. It is generally diagnosed at a late stage, by endoscopy, which is 
invasive and lacks both specificity and sensitivity. At the moment, there are no 
biomarkers to improve the accuracy of diagnosis.  
The modification of cell glycosylation patterns is a recognized hallmark of 
cancer, explored in non-invasive diagnostic, therapeutic decision, disease monitoring as 
well as therapeutics. Moreover, abnormally glycosylated proteins have been proven 
capable of eliciting humoral responses. Autoantibodies are regarded as the new 
generation of tumor biomarkers, cable to amplifying events occurring in tumors and 
showing higher stability to proteolysis. Nevertheless, little is known about EC 
associated glycosylation nor and its immunogenicity.  
Based on these considerations, the first part of this work aimed to identify 
glycosylation patterns in serum associated with EC. Tn, sTn, T, sale, and sLe
x
, the most 
studied tumors-associated carbohydrate antigens, were screened by slot blotting.  The 
levels of Tn, sTn, and sLe
a
 antigens were found significantly increased in the serum of 
EC patients, when compared to a control group of matched age and gender, without 
known malignancy. Moreover, the combination of the Tn and sTn antigens allowed the 
best discrimination between EC and controls (93.8% sensitivity and 100% specificity). 
Still, the expression of these antigens in the corresponding EC tissues, estimated by 
immunohistochemistry, showed a lack of correlation with the observations made in 
serum. Data suggests that glycosylation patterns of serum are mostly influenced by 
proteins that are not directly secreted or released from tumor cells, even though their 
contribution cannot be excluded.  
The second part of the work aimed to identify humoral responses against 
proteins carrying the sLe
a
, a glycosylated biomarker associated with increased potential 
of cellular migration and metastasis. The analysis of the IgG profile of the samples 
showed increased expression of IgG subclasse 1 (IgG1) in EC patients. De novo 
produced IgG1 were found to carry sLe
a
, accounting for the increase in the levels of 
this glycan in the serum of EC patients. Even though the biological events underlying 
these observations remain to be clarified, this may allow improving the sensibility and 
specificity of the serological test for sLe
a
 (CA19-9 test). Using a combination of 
immunoprecipiations and western blotting techniques it was further demonstrated, for 
the first time, that tumor proteins carrying sLe
a
 could elicit IgG1 production. 
Furthermore, experiments using desialylated proteins confirmed that the expression of 
sLe
a
 expression was determinant for IgG1 recognition.  
These observations and the future identification of the immunogenic proteins 
carrying sLe
a
 will allow determining the clinical value of this explorative work and 
guiding the development of autoantibody-based serological tests.  
Altogether, important insights have been provided to guide the development of 
non-invasive serological tests for the detection of EC. 
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I. Introduction  
This work addresses the clinical value of glycosylation in esophageal cancer 
envisaging non-invasive diagnosis. It further explores the possibility of having a humoral 
response triggered by changes in the glycosylation patterns of tumor tissues and its clinical 
value. 
1. Overview on esophageal cancer 
 Esophageal cancer (EC) is the 8th most common cancer and the most common 
cause of cancer death in the world [1, 2]. This malignancy, constitutes 7% of all 
gastrointestinal cancers and it is one of the most aggressive and lethal of all cancers [3, 4]. 
Their incidence varies with geographic distribution throughout the world, possibly 
reflecting differences in exposure to specific environmental factors, individual lifestyle, 
socioeconomic pressures, and diet and nutrition as well as genetic polymorphisms [5-7]. 
Incidence is more prevalent in the so-called “Asian esophageal cancer belt’’, extending 
from eastern Turkey through the southern former Soviet Union Iraq, Iran, and into western 
and northern China, Hong Kong, Japan [3, 6]. However, the incidence of esophageal 
cancer is largely increasing in the Western population, namely in France, Portugal and 
northern Italy [1, 8]. This suggests that specific environmental factors play a major role in 
the etiology of this malignancy [3]. 
Histologically, the EC has two main forms: the esophageal squamous cell 
carcinoma (SCC) and esophageal adenocarcinoma (AC), each are distinct etiological and 
specific risk factors [3, 7, 9, 10]. SCC is a multifactorial process associated with a variety 
of risk factors, that leads to a sequence of histopathological changes involving esophagitis, 
atrophy, mild to severe dysplasia, carcinoma in situ and finally, invasive cancer [3, 5]. 
Particularly epithelial dysplasia is regarded as the principal precursor lesion of SCC cancer 
[6]. On the other hand adenocarcinoma is frequently associated with gastroesophageal 
reflux disease (GERD) [11, 12]. That is known to lead to Barrett´s esophagus (EB), an 
acquired metaplastic abnormality in which the normal stratified squamous epithelium 
lining of the esophagus is replaced by an intestinal-like columnar epithelium [13-15] The 
carcinogenesis cascade after metaplasia, involves progression to low grade dysplasia, high 
grade dysplasia and finally the adenocarcinoma as demonstrate in figure 1 [8]. More than 
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90 % of esophageal cancers are either SCC and less than 10 % are AC [16, 17] but the 
incidence of SCC has been decreasing whereas that of adenocarcinoma has been 
dramatically increasing, particularly in Western populations [3, 8, 10]. This increase may 
be due, in part, to increases in the prevalence of obesity and associated gastroesophageal 
reflux diseases [18]. 
Figure 1. Proposed mechanism of inflammation in the development of metaplasia-
dysplasia-adenocarcinoma of the esophagus (adapted from [8]). 
 
The stage of disease at esophageal carcinoma is, so far, considered the most 
important predictor of survival, but during the early stages of EC, absence of symptoms is 
very common and the dysphagia is a late symptom that frequently accompanies the 
advanced stage of the disease [18-20]. Thus, this malignancy has an extremely poor 
prognosis with an overall survival of 20 % at 3 years [20] and the 5-year recurrence rate 
was 71 % [21, 22]. In resume, due to late diagnosis, rapid growth and spread, and high rate 
of recurrence, EC has a poor prognosis [23], and the conventional treatment options 
frequently include radical esophagectomy [26]. Preoperative and postoperative 
chemotherapy has been shown to improve survival compared with surgery alone, the 
addition of concurrent radiotherapy to preoperative chemotherapy improves rates of 
curative resection, reduces local tumor recurrence, and achieves a significant rate of 
pathologic complete response [24]. Ongoing research currently involves evaluating new 
regimens of chemotherapeutic drugs, as well as the incorporation of targeted molecular 
therapies, making of the molecular characterization of EC a key research field [19]. 
The diagnostic of EC is done by endoscopy and biopsy [19, 25]. However, 
endoscopy screening is invasive, costly and lack accuracy [26] since about 20 % of early 
esophageal cancer lesions are barely visible to the naked eye [19]. Further, this method 
suffers from poor specificity and sensitivity, which typically results in detection of the 
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disease only at an advanced stage [25], and consequently reduced overall survival. 
Individuals presenting histological alterations associated with an increased risk of EC, in 
particular patients with EB [19].  
Molecular and cellular markers for esophageal cancer have not been as extensively 
investigated as others gastrointestinal tract tumors [17]. However, several in situ studies 
report specific alterations in proteins, genes and metabolic pathways in EC, with some 
clinical value in diagnosis, prognosis and treatment [12, 17, 25]. Still, only few 
biomarkers, resumed in Table 1, have been tested in serological assays for non-invasive 
diagnostic of EC. These include squamous cell carcinoma antigen (SCCA), Cyfra 21.1, 
Carcinoembryonic antigen (CEA) and sialylated Lewis (a) antigen (CA19-9) [17, 20]. 
SCCA consists of more than 10 protein fractions, which can be divided in two groups: acid 
SCCA and neutral SCCA where malignant squamous cells is found mainly in malignant 
cells [17]. CEA is a glycoprotein produced in normal cells that is overexpressed by 
adenocarcinomas [17]. CA 19-9 in serum is a carbohydrate present on mucins that are 
found in patients with malignancies like EC [17]. Cyfra 21.1 are molecules that structurally 
belong to the family of cytokeratins used for a wide range of neoplasms [17]. Nevertheless, 
of these biomarkers have not progressed to clinical practice due to the lack of sufficient 
sensitivity and specificity [11]. Therefore, at the moment, highly specificity and sensitivity 
biomarkers, for early diagnosis, aid therapeutic decision, or monitor disease, are still to be 
presented [20, 25].  
 
Table 1. Serum biomarkers of esophageal cancer and their sensitivities and 
specificities. 
 
Biomarkers Sensitivity (%) Specificity (%) References 
CEA 28-40 89 [20, 27] 
CA 19-9 23-34 82 [20, 28] 
SCCA 32-55 73 [20, 29] 
Cyfra 21-1 72 53 [29] 
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1.1. General considerations about glycans as cancer biomarkers  
Changes in the glycosylation of cell-surface proteins have been long recognized as 
hallmarks of malignant transformation [30], including esophageal cancer [4, 31, 32]. The 
disorganization of secretory organelles, the deregulated expression/activity 
glycosyltransferases, the availability of sugar donors for biosynthesis, are among some of 
the factors leading to these phenotypic changes [33]. Subtle alterations in the glycosylation 
of tumor cells can be often amplified by the over-expression of specific glycoproteins. 
Thus, identification of abnormally glycosylated proteins is regarded to increase both the 
sensitivity and specificity of glycoprotein-based cancer detection [34]. Tumor-associated 
glycans are frequently shared into the blood stream and may be explored as biomarkers. 
Some of these antigens, such as SLe
a
 (CA19-9), SLe
x
 (CD 15s), and sialyl-Tn (CA72-4) 
have already been introduced into clinical practice [30, 35].  
Also, tumor-associated glycans are known to induce the production of autoantibodies 
that can be found in the serum of cancer patients [32, 36]. Proofs have been presented that 
autoantibodies may be raised in early stages of carcinogenesis and even in pre-malignant 
lesions [37]. Autoantibodies are considered more stable than the corresponding epitopes, 
and capable of amplifying molecular changes occurring in the tumor [38, 39]. This allows 
detection long before achieving the critical tumor mass need to obtain measurable amounts 
of tumor-associated molecules in serum [40]. Despite its potential, the use of 
autoantibodies for cancer detection has not yet been implemented in clinical settings. This 
is expected to occur in the near future, as awareness grows about its clinical value. 
Autoantibodies may also play a key role in the development of novel therapeutics, as they 
can be used to pinpoint tumor-specific immunogens [41]. As such, the integrated study of 
glycosylation and glycosylation-associated autoantibodies may provide insights to guide 
the development of non-invasive diagnostics for EC. It may also allow the identification of 
novel targets for immune-based therapies. 
Based on these considerations, the Introduction section presents an overview on the 
role, biosynthesis and structural aspects of glycosylation. It then discusses the most studied 
tumor-associated glycans, which includes simple mucin-type O-GalNAc glycans, sLe
a
 and 
sLe
x
, and systematically addresses the available information about these glycans in EC. It 
finishes by addressing the clinical value of autoantibodies to tumor-associated glycans.  
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1.2. Glycosylation in mammalian cells: structure and biosynthesis 
Glycosylation is a common post-translational modification of proteins, and is 
required for the viability of mammalian cells [30, 42]. Glycosylation involves a covalent 
attachment of carbohydrate to a protein, catalyzed by glycosyltransferases, using specific 
sugar donor substrates Glycosyltranferases synthesized glycan chains, while glycosidases 
hydrolyze specify the glycan linkage [42]. The combine action of these enzymes in the 
endoplasmic reticulum and the Golgi apparatus, determine the glycosylation patterns that 
allows them to function as signaling, recognition, and adhesion molecules [42-44]. This 
glycans constitute a significant amount of the mass and structural variation in biological 
systems [45]. As such, cell surface glycans are involved in many physiologically important 
functions that include normal embryonic development, differentiation, growth, contact 
inhibition, cell–cell recognition, cell signaling, host–pathogen interaction during infection, 
host immune response, disease development, metastasis, intracellular trafficking and 
localization, rate of degradation and membrane rigidity [30, 42, 43]. 
There are two main types of glycosidic chain glycoproteins, N-glycans and O-
glycans. Both types of glycosylation often coexist in the same protein and in the same cell 
[30, 43, 44] and comprehend more or less elongated chains, normally terminated by either 
ABO blood group determinants of Lewis related antigens [30]. During malignant 
transformations, both chains experience structural alterations [46]. In this thesis, particular 
attention is going to be devoted to transformations occurring in O-glycans. 
O-Glycosylation refers to a class of carbohydrate chains O-linked to a serine or a 
threonine. [30, 44, 46]. The frequency of O-glycosylation of glycoproteins is high, 
particularly on secreted or membrane-bound mucins. These proteins are high-molecular 
assemblies predominantly expressed in the glandular epithelia [30], and present several 
serine (Ser) and Threonine (Thr)-rich tandem repeat regions known to be O-glycosylated 
[47, 48]. 
O-Glycans protect underlying proteins as well as epithelial cell surfaces, maintain 
protein conformations, control active epitopes and antigenicity; they participate in cell 
adhesion, binding to microbes and in the immune system [47]. They may determine the 
cell surface expression and function of cell surface receptors and may be involved in 
growth regulation [48]. 
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The biosynthesis pathways of O-glycans occur in the Golgi complex, and 
comprehend sequential enzymatic steps that typically rely upon glycan structures produced 
by the previous enzyme to produce the substrate for the next [42]. O-Glycosylation is 
initiated by the transfer of N-acetyl-glactosamine (GalNAc) from a sugar donor UDP-
GalNac on hydroxyl groups in serine (Ser) or threonine (Thr) residues [30]. A large of a 
family of proteins, constituted by more than 15 different isoforms in mammals, showing 
high overlapping substrate specificity, determine the sites and density of O- glycosylation 
[30]. These enzymes are termed poplypeptide N-acetyl-galactosamineyltransferases 
GalNac-transferases (ppGalNac-Ts) and catalyze the formation of the Tn antigen 
(GalNacα-O-SerThr) [36].  
After the formation of Tn, chain extension may be terminated by sialylation, by 
sT6GalNac I-II [44, 48], responsible by the transfer of an N-acetyl-neuraminic acid 
(Neu5Ac) to the GalNAc residue of a Tn structure, generating the sTn antigen (Neu5Acα2-
6GalNacα-o-Ser/Thr) [36, 49] However, sTn presents a restricted pattern of expression in 
healthy tissues [50].  
The elongation of O- glycosylation continues when the Tn antigen is the substrate for 
core 1 β1-3 galactosyltransferases (C1GalT) or T synthase, that depends of molecular 
chaperone Cosmc, originating the core 1 or T antigen structure [36, 49]. The T antigens 
can also be sialylated by sT3Gal-I/II resulting in the S3T antigen (Neu5Acα2-3Galβ1-
3GalNAcα-O-Ser/Thr) or by sT6GalNac-II/III and IV, originating the S6T antigen (Galβ1-
3(Neu5Acα2-6) GalNAcα-O-Ser/Thr). If these enzymes act coordinately the resulting 
product is the disialyl-T antigen (dsT) (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-O-
Ser/Thr). Sialylation stops O-chain elongation [46, 48]. Alternatively, in the presence of 
core 3 β1-3N-acetylglucosaminiltransferase (C3GnT), the core 3 (GlcNAcβ1-3GalNAcα-
O-Ser/Thr) antigens is generated [36]. This antigen can be a precursor of core 4 
(GlcNAcβ1-6(GlcNAcβ1-3)GalNAcα-O-Ser/Thr) by action of M type β1-6-N-
acetylglucosaminetransferase (C2GnT-2) [30]. Nevertheless, the Tn antigen can also be 
sialylated by sT3Gal-I/II resulting the S3T antigen (Neu5Acα2-3Galβ1-3GalNAcα-O-
Ser/Thr) or by sT6GalNac-II/III and IV which originating the S6T antigen (Galβ1-
3(Neu5Acα2-6) GalNAcα-O-Ser/Thr). If these enzymes act coordinately the resulting 
product is the disialylate-T antigen (dsT) (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-O-
Ser/Thr). Such as the previous sialyltransferase, these also stopping the elongation [46, 48].  
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Though if not happen these sialylation the elongation of the T antigen continues with 
the action of the β1-6 N-acetilglucosaminiltransferase (C2GnT-1/3) results in the formation 
of core 2 (GlcNAcβ1-6(Galβ1-3)GalNAcα-O-Ser/Thr) [30]. The schematic representation 
is shown in the figure below, figure 2. 
 
Figure 2. Biosynthesis of O-glycans of mucins common with the main tumor 
associated antigens from the precursor Tn and the action of N-
acetylgalactosaminyltransferases (ppGalNAc-Ts); sialyltransferases ST6GalNAc,; 
core 1 β1-3 galactosyltransferase (C1GalT); core 3 β1-3 N-
acetylglucosaminyltransferase (C3GnT); sT3/sT6Gal Core 2 β1-6-N 
acetylglucosaminyltransferase (C2GnT). (Adapted from [30]). 
 
 Core structures 1-4 in particular are elongated by Gal- an GlcNac-tranferases and/or 
terminated by Fuc-, sialyl-, GlcNac- and /or sulfo-transferases in many different ways [48] 
however the most common O- glycan core structures are cores 1 and 2 [46, 48]. 
The extension cores structures may be further extended, by the action of N- 
β3/4acetilglucosaminiltransferase (β3/4 GnT) and β3/4N-acetilgalactosiltransferase (β3/4 
GalT), resulting in the formation of type 1 (Galβ1-3GlcNAc-R) and type 2 (Galβ1-
4GlcNAc-R) chains [30, 49]. These chains are expressed on the surface of the esophagus, 
stomach and duodenum glands and not in human epithelia tissues [40, 54-56]. Another 
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modification, can occur in these chains, by action of fucosyltransferases and 
sialyltransferases [30], as shown in figure 3. In type 1 chains, FucT-III originates the Le
a
 
antigen (Galβ1-3GalNAcα-O-Ser/Thr), that can be a precursor for FucT-I, that transfers a 
fucose to galactose residue resulting in the Le
b
 antigen (Fucα1-2Galβ1-3(Fucα1-
4)GlcNAc-R) [30, 49]. Type 2 chains may originate the Le
x
 antigen (Galβ1-4(Fucα1-
3)GlcNAc-R) and Le
y
 antigen (Fucα1-2Galβ1-4(Fucα1-3)GlcNAc-R), that result from the 
transfer of fucose to GlcNac residue by act of FucT-IV/ VI/ IX and FucT- II, respectively 
[30, 49]. These structures also can be sialylated by sT3Gal-III generating the sLe
a
 
(NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAc-R) antigen and by sT3Gal-IV/VI sLex antigen 
(NeuAcα2-3Galβ-4(Fucα1-3)GlcNAc-R) [30, 47]. The chain type 2 are most common in 
non-pathological condition [40, 54, 55]. 
 
 
Figure 3. Schematic representation of the biosynthesis of Lewis antigens. R represents 
precursor carbohydrate chain. Fuc-T, fucosyltransferase; Le
a
, Le
b
, Le
x
, Le
y
, sLe
a
, 
sLe
x
, sT3Gal, a2,3-Sialyltransferase (Adapted from [30]).  
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1.3. Abnormal glycosylation in cancer 
Abnormal protein O-glycosylation is considered a hallmark of malignant 
transformations [43, 51]. These alterations are present on the cell surface of cancer cells, 
thus easily accessible to antibodies or lectins as tissue biomarkers. Moreover, they are 
often expressed in the circulation, either on secreted products or by shedding from cell 
surfaces, and therefore may be explored in serological assays [34]. 
One of the main structural change results from a premature stop of O-chain 
elongation, normally by sialylation [48, 52]. These events, lead to the expression of a 
family of low molecular weight O-glycans that includes the Tn and T antigens and their 
sialylated counterparts [32]. Cell-surface and secreted mucins are major carriers of cancer 
associated O-glycans. Since these proteins present several repetitive sequences rich in 
serine and threonine, they amplify alterations in O-glycosylation [46]. As a result, short-
chain tumor-associated O-glycans are often termed, in the literature, “simple mucin-type” 
O-GalNAc glycans [44]. These alterations stem from the disorganization of secretory 
pathway organelles (ER and Golgi) in cancer cells and altered glycosyltransferase 
expression [48]. Occasionally they may depend on mutations in a chaperone essential for 
glycosyltransferase function [53].  
 Another common structural feature of cancer cells is the expression of Lewis-type 
blood group antigens, sLe
a
 and sLe
x
, mimicking their normal expression on blood cells 
(monocytes and neutrophils) and, consequently, mimicking their potential for migration 
through binding to endothelial cell selectins [48, 54, 55]. It has been also demonstrated that 
sLe
a
 and sLe
x
 are ligands of endothelial leucocyte adhesion molecule 1 (ELAM-1) in 
endothelial cells [32]. Moreover, cancer cells use these structures to adhere to activated 
endothelial cells events which have been recognized as promoters of haematogenous 
dissemination and metastisation [48]. As a result, sLe
x
 and sLe
a
 are generally 
overexpressed in carcinomas of several origins, e.g. cancerous gastric mucosa [48], breast 
[44, 49], head and neck [56] colon, lung, ovary [34]. 
Thus, simple-mucin type O-glycans, in particular sTn, as well as sLe
x
 and sLe
a
 are 
among the most studied and well characterized tumor-associated glycans. Moreover, these 
antigens have been transposed to clinical practice and explored as serological markers [57, 
58] 
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1.3.1.  T, Tn, sTn antigens 
 
Tn, siayl-Tn, T are present in approximately of all 90 % of  carcinomas specifically 
the gastrointestinal tract [48], colon [54], stomach [59] ovarian [48], breast [32], bladder 
[60], breast [44] lung [34] head and neck [56] among other tumors [61]. These antigens are 
generally absent from the normal tissue healthy individuals. However, sTn expression 
seems to be closely related to the upper digestive tract, still its expression is regulated and 
restricted to some specific cell types such as squamous cells in salivary glands and 
esophagus [22, 62]. 
In particular, T and Tn and sTn antigens often occur in advanced stage tumors [48, 
54]. But sTn is also aberrantly detected in premalignant lesions neoplastic of the 
gastrointestinal tract [59, 63]. sTn has been also associated with a poor prognosis in several 
types of cancer including colon, gastric, breast and ovarian cancer [44, 48, 54]. It has also 
been demonstrated that the de-novo expression of sTn leads to major morphological and 
cell behavior alterations in gastric and breast cancer cells [50]. Sialyl-Tn is able to 
modulate a malignant phenotype inducing a more aggressive cell behavior, such as 
decreased cell–cell aggregation and increased ECM adhesion, migration and invasion [59]. 
Thus, simple-mucin type O-glycans are useful biomarkers for prognosis, diagnostic 
value and therapeutics [42, 44, 48]. In particular, the sTn antigen is currently explored as a 
serological biomarker throughout the CA72-4 assay. Raised CA72-4 concentration has 
been shown in patients with gastric, colorectal and pancreatic carcinomas [58, 64]. In 
gastric carcinoma, CA72-4 has been shown to be useful as an independent prognostic 
factor, and a predictor of tumor recurrence CA72-4 has also been proven to be an 
independent prognostic factor in pancreatic cancer [65]. 
The association of sTn with malignancy has also led to the development of an anti-
cancer vaccine termed Theratope, comprehending a synthetic sTn coupled to the 
immunogenic-carrier keyhole limpet haemocyanin (KLH) [50, 66]. Tests in animal models 
and humans for breast and ovarian cancers have showed that the antigen is safe and 
produces a strong immune response against these tumors [67]. Recently, this vaccine has 
failed to provide an increased overall survival in phase III clinical trials for advance stage 
breast cancer. This was attributable to erroneous design of the study and research is 
ongoing to develop novel therapeutics based on these antigens [50]. 
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These cancers associated antigens therefore are useful biomarkers for prognosis, 
diagnostic value and therapeutics [42, 44, 48, 54].  
 
 
Figure 4. Structures O-glycosylated related in cancer (Adapted from [68]). 
 
In cancer cells, many of the glycosyltransferases involved in O-glycan biosynthesis 
are -up or -down- regulated [48, 54, 69]. The increased expression of the T antigen in 
colon cancer tissues may be due to decreased activity of the C3GnT synthesizing core 3 
structures, that favors core 1 synthesis by core 1 C3GnT, since both enzymes compete for 
GalNac-terminating substrates [33, 36, 48]. On the other hand, a down-regulation of 
C1GalT-1, resulting in the accumulation of Tn and sTn antigens, has also been observed in 
tumors [33]. Other glycosyltransferases may also be up-regulated, namely C2GnT1/3. This 
would result in a net decrease in core 2 synthesis, and a loss of core 4 synthesis [44, 48] as 
demonstrated in rat colonic mucosa [54]. A down-regulation of core 2 may lead also, an 
accumulation of T and sTn structures [33].  
The up-regulation of sialyltransferases is also a relevant feature behind the 
premature O-glycosylation in cancer [33, 59]. So, the up-regulation of this enzyme in 
cancer cell might indicate that a specific signaling pathway as been activated [33, 47, 62]. 
Some studies, have shown that an overexpression of sT6GalNac-I by Ras oncogene 
overexpression, leads to the over-expression of sTn [33]. Several other studies have also 
highlighted a correlation between sTn expression and the expression of sT6GalNac-I [36, 
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62]. The sT6GalNac-I and C2GnT are also known to compete for the same substrate, and 
the competition between these enzymes may determine the switch from the core 2 to more 
simple and sialylated O-glycan structures [33]. Brockhausen et al. further suggests that 
C2GnT is down regulated during differentiation in colon carcinogens leading to sTn 
biosynthesis [54].  
The overexpression of sT3Gal-I, responsible by the sialylation of the T antigen, has 
also been observed in primary breast carcinomas and relates to the grade of the tumor [36, 
44]. This sialyltransferase, even in the presence of unaltered levels of C2GnT1/3, has been 
proven capable of inducing a shift from core 2 to sialylated core 1 structure [33].  
The over-expression of simple mucin-type O-glycans has also been attributed to a 
rearrangement of a Golgi protein, as observed in colon cancer cells [48, 70]. The 
rearrangement of Golgi enzymes may prevent the synthesis of essential intermediates for 
subsequent enzymes or the premature synthesis of terminal structures [42, 48]. Also, the 
sequential addition of sugars in specific Golgi compartments is also controlled by the 
relative activities of glycosyltransferases or sulfotransferases acting on common acceptor 
substrates [44, 47, 48]. If these enzymes are present in the same Golgi compartment, 
competition may take place, which may unbalance biosynthesis [48, 54]. Change in metal 
ion concentrations and pH in the Golgi have also been reported in tumors, and are known 
to affect the activities of glycosyltransferases [47]. 
Alternative, premature stop in O-glycosylation may be induced by the loss of some 
chaperones [42]. A somatic mutation in the gene Cosmc that encodes a chaperon that is 
required for expression of active T-synthase, the enzyme responsible for the T antigen has 
been reported [53, 62] This loss leads to an accumulation of Tn epitope, which can be 
converted to sTn antigen, if this sT6GalNac-I is up-regulated [62]. 
1.3.2. sLe
a
 and sLe
x 
Sialylated Lewis antigens, namely sLe
a
 and sLe
x
, have been found over-expressed 
in gastric [48], breast [44, 49], head and neck [56] colon, lung, ovary cancers [34], whereas 
no or low positivity was detected in the corresponding histological healthy tissues [71]. 
The expression of these antigens is not restricted to O-glycans, as they can also be found in 
N-glycans as well as in glycolipids The over-expression was associated with increased 
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2,3-sialyltransferase and/or 1,3/4-fucosyltransferase activities. Alterations in gene 
expression of these enzymes have also been reported [49, 52]. 
Sialyl-Le
a
 and sLe
x
 on cancer cells are able to bind to endothelial cells through E-
selectin [48, 54, 55]. This interaction has been proposed as a factor in the attachment of 
cancer cells to the endothelium, and to contribute to promote invasion and metastasis [48]. 
The expression of these structures appears to be a marker of poorly differentiated 
adenocarcinomas and is associated with invasive and high proliferative property of the 
tumors, metastasis and poor clinical outcome [32, 48, 54]. 
The significance of sLe
a
 and sLe
x
 to cancer dissemination as led to attempts to use 
them, not only as cancer biomarkers, but also as therapeutic targets. One therapeutic 
strategy is based on the reduction of Le
x
 synthesis by using competitive disaccharide 
substrates as decoys [72]. Antisense strategies, directed to a1,3/4-fucosyltransferase, have 
also proven successful in reducing liver metastisation in a mouse model [73]. The 
identification of the mechanisms controlling gene expression (methylation, transcription 
factors, among others) and the identification of tumor-specific protein carriers will permit 
to improve their usefulness as cancer biomarkers and provide novel targets for 
immunotherapy [30] 
1.4. Alteration in patterns of O-glycans in esophageal cancer 
Very few studies have addressed the expression of tumor-associated glycans, 
namely the Tn, sTn, T, sLe
x
, and sLe
a
, in EC. 
The results from a systematic review on the literature, presented from 20.07.12 to 
6.12.12, about this subject has been presented in table 1. A total of 14 studies have 
evaluated at least one of the above described tumor-associated glycans in the esophagus. 
Three studies involved histologically normal epithelium from healthy individuals; three 
were on pre-malignant lesions and 12 on EC, 7 of which SCC, 2 EC, and 5 presented no 
information regarding its histological grade.  
Simple mucin-type O-glycans are rarely expressed in normal tissue healthy 
individuals. However sTn expression seems to be closely related to the upper digestive 
tract, this expression is regulated and restricted to some specific cell types such as 
squamous cells in salivary glands and esophagus [22, 50]. Some studies have shown that 
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sTn is expressed in the submucosa and lamina propria of normal squamous epithelium in 
the esophageal glands. However, sTn was no detected in cells of either the basal layer or 
the parabasal layer using two different antibodies B72.3 and TKH2 [22]. Still, 
contradictory results were presented by De Faria et al., that did not observe sTn in a series 
of 8 cases [31]. 
De Faria et al. showed that sTn was mostly absent from dysplastic tissues, but always 
present in EB, which are precursors of AC. Approximately half of the EB cases also 
expressed the Tn antigen [31]. The T, sLe
x
, sLe
a
 antigens were not evaluated. Sialyl-Tn 
was found in 50% of SCC and always in EC [70]. This data suggests that sTn may be 
characteristic EC and their precursor lesions [22]. The sLe
x
 was detected in approximately 
30% of EC (31% in SCC and 28% in EC) while the sLe
a
 was found in 40-50% of EC, 
irrespectively of their histological nature [4, 74]. The T antigen has not been evaluated.  
The collected data suggests that the Tn, sTn, sLe
x
 and sLe
a
 are expressed in EC but 
not in healthy esophagus epithelium [22, 31]. This studies further highlighted that these 
antigens are not correlated with TMN and other clinic-pathological variables, but are 
associated with poor survival and are present in early stages of carcinogenesis [4, 22, 74-
76]. However, more studies should be conducted to validate these observations and 
establish a glycosylation pattern for EC. 
 Seven studies have also addressed the expression of tumor-associated glycans in the 
serum of EC (Table 2). Six evaluated the sLe
a
 antigen with variable results (16-48% 
positive cases) [20, 77, 78]. Türkyilmaz et al. analyzed 330 ESSC cases and only 16% of 
the cases were considered positive [77]. This contrasted with the higher sLe
a
 positivity 
observed by Mealy et al. for 33 AC [20]. This suggests that sLe
a
 is more expressed in AC 
than in SCC, however more studies are needed to confirm these observations. The sTn 
antigen was evaluated in two studies [23, 79], thus not allowing to with draw conclusions 
about their biomarker value. The Tn and sLe
x
 antigens have not been evaluated to the date. 
 
 
 
 
I. Introduction 2012 
 
 
Department of Chemistry  
Aveiro University  17 
Table 2. Summary of studies that correlated aberrant glycosylation and esophageal 
cancer 
  
n 
 
Positive cases (%) 
 
 
Method 
 
Ref 
 
Tn 
 
sTn 
 
T 
 
sLe
x
 
 
sLe
a 
 
         
Tissue         
Normal 20 - 0 - - - Immunohistochemistry [22] 
20 - - - - 0 Imununohistochemistry [74] 
 8 100 0 - - - Imununohistochemistry [31] 
Dysplasia 12 - 8 - - - Immunohistochemistry [22] 
 11 - - - - 4 Immunohistochemistry [74] 
EB 29 48 100 - - - Immunohistochemistry [31]  
EC
1
 89 - - - 25 39 Immunohistochemistry [80] 
 74 - - - - 40 Immunohistochemistry [74] 
ESSC 130 - - - 31 32 Immunohistochemistry [4] 
 54 - - - - 52 Immunohistochemistry [76] 
 86 - 47 - - - Immunohistochemistry [22] 
 16 75 - - - - Immunohistochemistry [70] 
 84 - 50 - - - Immunohistochemistry [75] 
EA 7 100 100 -00 - - Immunohistochemistry [31] 
         
Serum         
EC 50 - 16 - - - ELISA [23] 
 50 - - - - 48 ELISA [77]  
 40 - - - - * ELISA [81]  
SCC 25 - - - - 24 ELISA [20] 
 330 - - - - 16 ELISA [78] 
 43 - * - * * Microarrays [79] 
AC 33 - - -  42 ELISA [20] 
* The percentage of positive cases was not reported and could not be inferred from the data 
provided in the manuscripts. Still, significant correlations with the pathological condition 
were reported in both cases (p<0.05). 
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 1.5. Cancer associated antibodies 
Antigenic changes in tumors can be recognized by the immune system leading to 
the production of immunoglobulins [82]. This promotes a very efficient biological 
amplification of tumor-associated events, with antigenic tumor proteins as templates, 
allowing an indirect, more sensitive detection [38].  
The immune response is generated locally, or tumor-associated proteins can be 
processed by antigen-presenting cells and displayed by lymphocytes in the lymph node the 
tumor site [38]. This response may begin at an early stage as 5 years before a tumor is not 
clinically detectable and be detected in circulation [38, 40, 68, 83].  
However, small populations of tumor cells that create a humoral immune response 
at an early may not continue to malignancy and are eliminated [68]. Moreover, advanced 
stage cancers may not only be able to grow and thrive within the constraints of the immune 
system, but also have an inhibitory effect on inflammatory function and recognition of 
antigens thus avoiding a immune surveillance [84]. Thus, stage-specific humoral response 
patterns can be generated [82] and explored in clinical practice. 
Humoral responses can either be generated by a neo-epitopes or by enhanced self-
epitope presentation to major histocompatibility complexes or the T-cell receptors. 
Another hypothesis involves tumor cell lyses and the presentation of intra-cellular 
molecules to the immune system in an inflammatory environment [41]. This event also 
releases proteases that may unveil cryptic epitopes that may trigger an autoimmune 
responses [40].  
Although little is known about the origin of this immune response, it is now 
established that mutated proteins, misfolded, over-expressed, aberrantly degraded, 
aberrantly localized [38, 40] or aberrantly glycosylated proteins may induce autoantibody 
production [38, 85, 86]. The dominant immunoglobulins in autoimmune diseases and 
against tumor-associated antigens, is IgG with reactivity significantly greater within the 
IgG3 subclass [85, 87, 88]. In ovarian cancer patients, the immunoreactivities of IgG2 and 
IgG3 to nuclear and membrane antigens, in all stages of the disease, were greater than that 
observed in controls or patients with benign disease [85]. 
Some studies have reported the presence of autoantibodies against certain cellular 
proteins, including p53 and procathpsin D, using western blotting in advanced ovarian 
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cancer patient and correlated these observation with poor prognosis and poor survival [86, 
89, 90].  
Lacombe and colleagues using proteomic approach and serologic screening of 
breast cancer patients related autoantibodies against five antigens (GAL3, PAK2, PHB2, 
RACK1 and RUVBL1), these antigens are related with early-stage breast cancer [83] 
The most common techniques used in the identification of autoantibodies and 
corresponding tumor-associated antigens are described in Table 2, and include the 
serological proteome analysis, immunoprecipitation of antigens followed by mass 
spectrometric analysis and antigen microarrays [39]. However, the most used remain 
ELISA (sandwish enzyme-linked immunosorbent assay) and Western blot [86, 91]. 
 
Table 3. The methodologies that enable to detected autoantibodies 
 
Method 
 
 
Description 
 
Ref 
ELISA Tumor lysates are incubated with commercial antibody 
arrays so that each antigen is immobilized on a 
different spot. 
[37, 38, 40, 87, 91] 
Microarrays The TAAs may be directly spotted on microarrays and 
probed with specific human sera. 
[38, 40, 41, 82, 91, 92] 
Phase display  Autoantibodies in patient sera are captured by the 
phage display library through successive rounds of 
immunoprecipitations and the corresponding TAAs are 
sequenced for identification 
[38-40] 
Serologic 
Identification 
of Antigens 
Recombinant 
Expression 
(SEREX) 
Identification of TAAs by screening patient sera 
against a cDNA expression library obtained from the 
autologous tumor tissue 
[38-41] 
Serological 
Proteome 
Analysis 
(SERPA) 
Proteins from tumor tissue are separated by 2D 
electrophoresis, transfered onto membranes and probe 
with sera from healthy individual and cancer patients. 
Then the profiles are identified by mass spectrometry 
(MS) 
[38, 40, 91] 
Western Blot The TAAs are transferred to a membrane and are 
incubated with autoantibodies against target protein 
[40, 41, 90, 91, 93] 
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In resume, the identification of autoantibodies in the serum of cancer patients has 
created opportunities for a novel source of cancer biomarkers for cancer screening, 
diagnosis and immunotherapy [41, 83, 91]. There are various reasons for this, these 
autoantibodies can be detected in early and asymptomatic stage; autoantibodies are found 
in serum of patient and they are accessible to screening; and for last, autoantibodies are 
inherently stable and have a long half-life (7 days) than the corresponding epitopes, 
because they are generally not subjected to the types of proteolysis experienced by all other 
proteins [39, 40, 83, 92] 
 1.6. Autoantibodies present in esophageal cancer 
Few studies exist addressing the humoral response against EC tumor-associated 
antigens, namely against intra-tumoral p53 protein accumulation [94, 95]. Others reports 
related autoantibodies against shock protein 70 (Hsp) and peroxiredoxin IV (Prx) in SCC 
[91, 93]. In particular, Fujita et al., described elevated levels of autoantibodies against 
Hsp70 in 93.7% of the sera from 16 patients with SCC, using western blot and a 
proteomics-based approach. Even though the levels of autoantibodies were significantly 
higher in the patients, they could also be found in healthy individuals, demonstrating 
autoantibodies can also be present in non-pathological conditions [93]. Kilic and 
colleagues also demonstraed, using microaarays in 18 patients, the presence of serum 
autoantibodies for 51 AC associated proteins. The most discriminating protein was FasL 
with 88.9% sensitivity and 100 % specificity [96]. A report concerning autoantibodies for 
the oncogenes CDC25B has also been presented. This showed higher sensitivity and 
specificity than tumor markers CEA, SCC-A and CYFRA21-1 (Table 1) for diagnosis of 
SCC [97]. Humoral responses for oncogene Bmi correlated with tumor stage and lymph 
node status [98]. All together, these reports point out that autoantibodies are promising, 
and more accurate biomarkers when compared to the ones presented in Table 1, for the 
non-invasive diagnostic of EC. 
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1.7. Humoral response against aberrant glycosylation 
As described above the immune response can be the consequence of several 
mechanisms, including aberrant glycosylation [86, 88, 90]. Studies showed that Tn-
glycoform induces potent IgG responses in MUC transgenic mice and cancer patients, that 
had no preexisting and all developed detectable IgG Tn-MUC1 antibodies after vaccination 
and a lower expression in healthy tissues [37, 99]. 
Blixt and colleagues, demonstrating using O-glycopeptide array-based assay, raised 
levels of autoantibodies against Tn-, core 3- and sTn-glycoforms in breast cancer patients 
[68]. These studies also concluded that these autoantibodies are found more frequently and 
at higher levels in early stage breast cancer patients than in women with benign breast 
diseases or healthy woman [68]. Also, individuals with higher autoantibodies titers against 
mucins have a better prognosis than patient with free circulating anti-mucin antibodies as 
(Core 3/Tn/sTn-MUC1) [37, 87, 99]. Similar results were found by Pedersen et al., in sera 
of colon cancer patients, with sTn-MUC1, and resulted in the detection of 79% of cancer 
patients, with a specificity of 92% [99]. However, autoantibodies for Tn- and sTn-MUC1 
glycoforms showed more specificity in cancer patients, whereas the core 3-MUC1 were 
also detected in patients with chronic inflammatory lesions [92]. Others studies, 
demonstrated circulating autoantibodies that recognized these structures in breast, 
pancreas, ovarian, prostate and colon cancer patients at the time of diagnosis [37, 87, 99]. 
No difference in these autoantibody levels were detected among stage I, II, or III in 
colorectal cancer while levels were lower in patients with metastasis [99]. The same was 
found in pancreatic cancer where serum autoantibodies levels were more strongly 
associated with levels status than clinical prognosis factors [100]. The subclass of 
immunoglobulin predominant against core3/sTn-MUC1 is IgG2 [85, 99]. 
Additionally, Ravindranath et al., showed the presence of autoantibodies IgG 
against sLe
x
 in melanoma cells and are correlated with potential endpoint to assess the 
therapeutic effectiveness of vaccine therapy [101]. 
In esophageal cancer patients there are no studies relating circulating autoantibodies 
and altered glycosylation/glycoproteins. 
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2. Aims and scopes 
 
EC has an extremely poor prognosis, an overall survival of 20 % at 3 years [20] and 
a 5-year recurrence rate of 71 % [21, 22]. It presents a poor prognosis due to late diagnosis, 
rapid growth and spread, and high rate of recurrence [23]. The diagnostic is mostly 
achieved by endoscopy which is invasive and fails to detect approximately 20% of early 
lesions, barely visible to naked eye [19]. Furthermore, this method has poor specificity and 
sensitivity and, at the moment, there are no biomarkers to improve the accuracy of 
diagnostic [20, 23]. 
The modification of cell glycosylation patterns is a recognized hallmark of cancer 
explored in non-invasive diagnostic, therapeutic decision, disease monitoring as well as 
therapeutics. Moreover, abnormally O-glycosylated proteins have been proven capable of 
eliciting humoral responses. Autoantibodies to tumor-associated antigens are regarded as 
the new generation of tumor biomarkers, as they are able to amplify events occurring in 
tumors and are more stable in circulation than the corresponding epitopes. Moreover, they 
can be used to pinpoint immunogenic proteins that may be explored in therapeutics. 
Despite this, little is known about EC associated glycosylation and no studies have been 
presented concerning its immunogenicity.  
Based on these considerations, this thesis aims to identify humoral responses against 
abnormal EC glycosylation. The first part of the experimental section devotes to the 
characterization of the glycosylation of a series of EC and corresponding sera. The Tn, 
sTn, T, sLe
x
, and sLe
a
 antigens, which are the most studied tumor-associated glycans, will 
be evaluated in an attempt to establish a glycosylation pattern for EC. The second part of 
the work will focus on the identification of humoral responses against EC proteins carrying 
abnormal glycosylations.  
The generated information will allow guiding future studies for the development of an 
autoantibody-based non-invasive diagnostic method for EC. Important insights on the 
immunogenicity of EC glycosylated proteins will also be generated.  
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3. Material and methods 
3.1. Overview  
The first part of this thesis devotes to establishing a serological glycosylation 
profile for EC by slot blotting. Four of the most studied tumor-associated carbohydrate 
antigens, that include the Tn, T, sT, sLe
x
, and sLe
a
, were screened. In addition, these 
antigens were evaluated in some of the corresponding EC tissues by 
immunohistochemistry, to highlight common patterns. The s3T and s6T antigens were also 
evaluated, for the first time, in EC tissues using the combination of enzymatic treatments 
and antibodies shown in Figure 5. The generated data was comprehensively analyzed to 
determine tumor-associated antigens presenting the highest discriminative power.  
 
 
Figure 5. The s3T and s6T antigens structures using the combination of enzymatic 
treatments. 
 
The second part of the thesis contemplated the characterization of the IgG profile of 
EC-associated sera and the mining of humoral responses against the EC proteins exhibiting 
altered glycosylation. Briefly, the proteins presenting altered glycosylation were recovered 
from EC tissues by immunoprecipitation and blotted with IgGs from the sera of EC 
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patients. The identification of immunoreactive bands allowed confirming humoral 
responses against tumor glycoproteins. An overview on the analytical strategy adopted is 
presented in Figure 6. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Overview on the analytical strategy. 
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3.2. Patient and sampling 
Sixteen patients (14 men and 2 women), mean age of 65 (age range 51–89), facing 
primary diagnostic with esophageal cancer (EC) in Portuguese Institute for Oncology of 
Porto (IPO-Porto, Portugal) between March 2011 and May 2012, have been elected for this 
study. According to the patient’s clinical records, 7 were classified as squamous cell 
carcinomas (SCC), 3 as esophageal adenocarcinomas (AC), whereas for 6 cases no 
information was available at the time of the study. None of these patients had received 
prior adjuvant therapy.  
Whole blood was collected from all of the patients in tubes without anticoagulant. 
The samples were kept at room temperature for approximately 1 h and then centrifuged for 
5 min at 3,000 rpm at room temperature. The supernatant (serum) was then collected and 
stored at -80ºC. Individuals within the same mean age and age range, without known 
neoplasia, were included as controls. The sampling also included 7 FFPE (Formalin-fixed 
paraffin embedded) tissues, (5 SCC and 2 AC) and the corresponding adjacent mucosa. All 
procedures were performed under the scope of Foundation for Science and Technology 
(FCT) financed project PIC/IC/82716/2007, under the approval of the Ethics Committee of 
IPO-Porto, after patient’s informed consent.  
3.3. Immunohistochemistry for simple mucin type O-GalNAc glycans, sLe
a
, sLe
x 
and 
human IgG1 
FFPE tissue sections were screened for Tn, sTn, T, s6T, s3T, sLe
a
, sLe
x
 antigens 
and human IgG1 by immunohistochemistry (IHC) using the avidin/biotin peroxidase 
method. Briefly, 3 m sections were dewaxed with xylene, rehydrated with graded ethanol 
series and microwaved for 15 min in boiling citrate buffer (10mM Citric Acid, 0.05% 
Tween 20, pH 6.0). The slides were then exposed to 3% hydrogen peroxide in methanol for 
20 min. The expression of the Tn, sTn, T, sLe
a
, sLe
x
, antigens and human IgG1 were then 
directly evaluated using mouse monoclonal antibodies IE3, TKH2, 3C9, anti-sLe
a
 clone 
192, anti-sLe
x
 KM92, anti-human IgG1, respectively (Table 4). The expression of s3T was 
determined comparing the reactivity of the tissues with 3C9 antibody, before and after 
treatment with an (2→3)-neuraminidase from Streptococcus pneumonia (Sigma-
III. Material and methods 2012 
 
 
Department of Chemistry  
Aveiro University  32 
Aldrich) to yield the T antigen. The expression of s6T was evaluated comparing of the 
reactivity of the tissues with TKH2 antibody, before and after treatment with a 
recombinant β-(1-3)-Galactosidase from Xanthomonas campestris (R&D systems) to yield 
the sTn antigen. Prior to analysis, the sections were blocked with normal serum from 
Vectastain Elite ABC peroxidase kit (Vector Lab) for 30 minutes to avoid non-specific 
staining and then incubated with the enzymes, whenever the case, at 37ºC for 16 hours. 
The sections were then further incubated with specific antibodies at 37ºC for 16 hours. 
Afterwards the sections were washed with PBS-T (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 
1.3 mM KCl, 135 mM NaCl, 0.05% Tween 20, pH 7.4), incubated at room temperature for 
30 minutes with the diluted biotinylated secondary antibody, and then with Vectastain Elite 
ABC reagent (Vector Lab). After washing in PBS-T, the sections were incubated with 3,3-
diaminobenzidine tetrahydrochloride (ImmPACT™ DAB, Vector Labs) for 5 minutes at 
room temperature to visualize antibody binding sites. Finally, they were counterstained 
with Harri´s hematoxylin for 1 minute. Bladder carcinomas known to express the 
glycosylations of interest were used as positive controls. The negative control sections 
were performed by adding BSA (5% in PBS) devoid of primary antibody. A semi-
quantitative approach was established to score the immunohistochemical labeling based on 
the intensity of staining and the percentage of cells that stained positively. The labeling 
was be assessed double-blindly by two independent observers and validated by an 
experienced pathologist. Whenever there was a disagreement, the slides were reviewed, 
and consensus was reached. 
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Table 4. Characterization of the primary antibodies used in this thesis.  
 
     Concentration (µg/mL) 
 
Targeted Antigen 
 
Antibody Isotype Host 
Specie 
Conjugate Company Western 
Blot 
Slot Blot IHC 
         
Tn 1E3 IgG Mouse - hybridome 1:15* 1.5:20* 1:10* 
         
sTn TKH2 IgG1 Mouse - hybridome 3:20* 3:20* 1:10* 
         
T 3C9 IgM Mouse - hybridome 1:15* 1.5:20* 1:10* 
         
sLe
a
 Anti-Human sLe
a
, clone 192 IgG1 Mouse - Santa cruz 
Biotech 
0.75 1 0.1 
         
 
sLe
x
 
Anti-human sLe
x, 
clone KM92 IgM Mouse - Millipore 1.25 1 0.2 
         
s6T 
1
 TKH2 IgG1 Mouse - hybridome - - 1:10* 
         
s3T
2
 3C9 IgG1 Mouse  hybridome - - 1:10* 
         
Human IgG1 Anti human IgG1, clone HP6069 IgG1 Mouse HRP Invitrogen 0.01 0.02 - 
         
Human IgG2 Anti-human IgG2, clone HP6014 IgG1 Mouse HRP Invitrogen 0.01 0.02 - 
         
Human IgG3 Anti-human IgG3, clone HP6047 IgG1 Mouse HRP Invitrogen 0.01 0.02 - 
         
Human IgG4 Anti-human IgG4, clone HP6025  IgG1 Mouse HRP Invitrogen 0.01 0.02 - 
         
* Dilution from culture supernatant  
* After treatment with 
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3.4. Expression of glycosylated antigens and IgG profiling in serum   
The expression of Tn, sTn, T, sLe
a
 and sLe
x
 antigens in serum was determined by 
Slot Blotting. Fifty micrograms of serum proteins diluted in TBS (100 mM Tris, 1.5 mM 
NaCl, pH 8.0) were slot-blotted on a nitrocellulose membrane (Whatman, Protan; pore size 
0.45 m) using the Hybri-slot apparatus (21052-014; Gibco BRL, Life Technologies). 
Equal amounts of BSA were used as negative controls. The membranes were first blocked 
with Carbo-Free Blocking Solution (SP-5040, Vector Laboratories) for 30 minutes at room 
temperature and incubated with the monoclonal antibodies presented in Table 4. The 
membranes were then washed with TBS-T (TBS with 0.5 % Tween 20) and incubated with 
either goat anti-mouse IgG1 heavy chain (Abcam; 1:35,000 in TBS), goat anti-mouse IgG 
(H+L; Jackson ImmunoResearch; dilution 1:30,000 in TBS) or rat anti-mouse IgM  (mu 
chain; Abcam; dilution 1:30,000 in TBS) horseradish peroxidase conjugates, depending on 
the primary antibody being evaluated. Controls for the sTn, sLe
a
, and sLe
x
 include samples 
digested with a -neuraminidase from Clostridium perfringens (Sigma), and for the T 
antigen samples digested a β-(1-3)-Galactosidase from Xanthomonas campestris (R&D 
systems). 
IgG subtypes 1, 2, 3, and 4 were also accessed by slot blotting using 15 g of serum 
proteins. In this case, after blockage with carbo-free, the membrane was directly incubated 
with mouse anti-human IgG1, IgG2, IgG3 and IgG4 (Invitrogen).  
Antibody-reactive bands were detected by enhanced chemiluminescence ECL 
prime (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Images 
were recorded using X-ray films (Kodak Biomax light Film, Sigma). The films were 
scanned in Molecular Imager Gel Doc XR+ System (Bio-Rad) and analyzed with 
QuantityOne software (v 4.6.3 Bio-Rad). All analyses were performed in triplicates, and 
the presented results are the arithmetic average of these measurements.   
3.5. Quantification of Total IgGs in serum  
The quantitative determination of human IgG in serum was determined by an 
immunoturbidimetric tests with the Olympus 2700 auto-analyzer using commercial 
Olympus kits. Briefly, human serum was diluted in TBS and polyethylene glycol and 
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mixed with polyclonal goat anti human IgG. The generated immune complexes or cause an 
increase in light scattering that correlates with the concentration of IgG in the serum. Light 
scattering is measured by reading turbidity at 700 nm in an Olympus 2700. IgG standards 
0.75-30.0 g/L were used to establish a calibration curve.   
3.6. Protein extraction from tumors 
Proteins were extracted from FFPE sections (3x10m) after deparaffinization of the 
tissue using Q-proteome FFPE Tissue Kit (Quiagen) according to the manufacturer’s 
instructions. The proteins were then recovered in the supernatant by centrifugation at 
14,000 g at 4ºC for 30 min. The remaining pellets were then washed with cold RIPA buffer 
(50 mM Tris-HCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM NaCl, 
pH 7.4) with 0.2 M NaOVa, Protease Inhibitor Cocktail (Roche) to increase protein yields. 
Total protein extracts were depleted of IgGs and other proteins with affinity for protein G 
by incubation with protein G-Sepharose beads (Sigma) for 4 h at 4 ºC. The amount of 
protein in each fraction was determined using the RC-DC kit (BioRad), based on a 
modification of the Lowry method. 
3.7. Isolation/Removal of immunoglobulins  
 Serum immunoglobulins were recovered by incubation with protein G-Sepharose 
beads (Sigma). Prior to use, the beads were equilibrated with PBS and then incubated with 
human serum at 4º for 4 hours under gentle rotation. The unbound material was then 
removed by centrifugation at 1,000 g and the beads were extensively washed with PBS. 
The immunoglobulins were then recovered in 0.2 M glycine pH 3.0 and the buffer was 
immediately exchanged to PBS, using Amicon Ultra centrifugal 10 kDa MWCO filters 
(Sigma), to avoid protein denaturation. The same procedure was applied to remove 
immunoglobulins from protein extracts isolated from tumor tissues.  
3.7.1. Isolation of sLe
a
 expressing proteins and western blotting 
Briefly, the immunoglobulin-depleted protein extracts dissolved in RIPA buffer 
(approximately 100 l) were incubated with mouse monoclonal anti-sLea IgG1 (Table 4) 
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for 16 h at 4ºC under gentle rotation, followed by incubation with protein G-Sepharose 
beads (Sigma) for 4 h at 4 ºC. The unbound material was removed by centrifugation at 
1,000 g for 10 min at 4ºC and the beads were washed extensively with RIPA buffer. Bound 
proteins were eluted by boiling in sample buffer (125 mM Tris–HCl, pH 6.8, 4% (v/v) 
SDS, 10% (v/v) glycerol, 0.02% (w/v) bromophenol blue, 10% (v/v) b-mercaptoethanol) 
for 10 min. Supernatants were subjected SDS–PAGE electrophoresis in 4-12% Mini-
PROTEAN TGX Precast Gels (BIORAD) and transferred onto an 0.45 m Immobilon-P 
polyvinylidene di-fluoride (PVDF, Millipore) membrane in 25 mM Tris–HCl, pH 8.3, 192 
mM glycine, 20% methanol at 50 mA for 2 h. Membranes were blocked with 1% carbo-
free (Vector laboratories) for 1 h at room temperature, incubated for 45 min with 
monoclonal anti-sLe
a
 IgG1 (Table 4), washed with TBS-T for 30 min, and finally 
incubated for 1 h with goat anti-mouse IgG1 heavy chain horseradish peroxidase conjugate 
(Abcam; 1:35,000 in TBS). After washing, the bound antibodies were revealed by 
chemiluminescence using the ECL prime Kit (BIORAD).  
The membranes were then submitted to mild stripping for further reproving. First 
the membranes were incubated with 1.5% glycine (w/v), 0.1% SDS (w/v), 1% Tween20 
(v/v) pH 2.2 for 10 min two times at room temperature, followed by PBS and TBS-T. The 
efficiency of stripping was checked by incubating the membrane with chemiluminescent 
detection reagent. The protein content in the bands was monitored using MemCode™ 
Reversible Protein Stain Kit for PVDF membranes (Pierce). 
3.7.2. Identification of humoral responses against tumor glycoproteins expressing 
sLe
a 
The proteins expressing sLe
a
, immobilized in PVDF membranes in section 3.7.1, 
were blotted with serum IgG from the corresponding patients, isolated as described in 
section3.7. These membranes were then incubated with mouse anti-human IgG1 
horseradish peroxidase conjugates (Table 4) and revealed by chemiluminescence using the 
ECL prime Kit (BIORAD). Afterwards, the membranes were then mild stripped as 
described in section 3.7.1, blocked with 1% carbofree (Vector Laboratories) and incubated 
for 16 h with an -neuraminidase from Clostridium perfringens (Sigma) at 37ºC. This was 
used as control experiment to determine the specificity of humoral responses against sLe
a
.  
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3.8. Statistical Analysis 
 The statistical tests used in this thesis included Student t-test for unpaired samples. 
Differences were considered to be significant when p < 0.05. Also, a chi-square test was 
used to analyze correlations between clinicopathological features and antigen expression 
patterns. A Principal Components Analysis (PCA) was used to extract correlations between 
samples regarding the expression of tumor-associated carbohydrate antigens. Receiver 
operating curves (ROC) were used to estimate the sensitivity and sensibility of tumor-
associated carbohydrate antigens in the serological detection of EC. The coefficient of 
correlation (R
2
) was used to estimate the degree of adjustment of sLe
a
 vs IgG/IgG1 plots to 
a linear regression model. 
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4. Glyco-serological profiling of EC 
 As described in detail in the Introduction chapter, alterations in the glycosylation 
patterns of tumor cells are considered a hallmark of malignant transformations [30]. These 
glycoproteins are often expressed in the peripheral blood circulation, either on secreted 
products or by shedding from cell surfaces [102]. Thus, several glycans are currently used 
as serum biomarkers in several cancers [59]. 
 Despite the biomarker value of cancer-associated glycans, little information exists 
about serological glycosylation patterns associated with EC. Moreover, few studies have 
addressed the expression of the most studied tumor-associated carbohydrate antigens, such 
as the Tn, sTn, T, sLe
a
, and sLe
x
 in EC. Thus, this chapter devotes to study the expression 
of these antigens both in the serum and EC tissues, with the intention of highlighting 
putative biomarkers.   
 
4.1 Results  
4.1.1. Screening of tumor-associated glycans in serum 
 
A set of 16 sera from EC patients was characterized in relation to the expression of 
Tn, sTn, T, sLe
a
, and sLe
x
, which are the most studied tumor-associated glycans, by slot 
blotting. Ten individuals with matched age and gender, and without known oncological 
disease were included as a control group. 
As shown in Figure 7B, the serological levels of sTn, T, sLe
a
 and sLe
x
 antigens 
were significant different between the two groups. The sTn and sLe
a
 were higher in the EC 
group (p<0.05) while T and sLe
x
 were significantly lower (p<0.001) when compared to the 
controls. The serum levels of the Tn antigens were also more elevated in the EC group, 
however this was not statistically significant. It was also attempted to correlate the 
expression of these antigens with clinicopathological nature of the tumor, sex, and age 
using a Chi-square test; however no correlations were found. 
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Figure 7. Serological levels of tumor-associated glycans sTn, T, sLe
a
 and sLe
x
 antigens 
in controls (n=10) and EC (n=16). A) Slot blotting for sLe
a
 showing a higher expression 
of this antigen in EC. B) Resume data from slot-blotting regarding the expression of Tn, 
sTn, sLe
a
 and sLe
x
 in serum. sTn and sLea were significantly increased in EC, whereas T 
and sLe
x
 were decreased. The Tn antigen was also increased, even though not statistically 
significantly, in the EC group. Data is presented as mean ± standard deviation (n=3 for 
each samples). * p<0.05; *** p<0.001 vs the preceding concentration. 
 
A Principal Components Analysis (PCA) was then applied to the generated data in 
an attempt to isolate groups based on the most discriminative antigens. The Scores plot 
presented in Figure 8 show that the PC1 and PC2 accounts for 68% of the sample, with 
PC1 presenting 45.8% and PC2 the remaining 21.9%. The scores plot (samples plot; Figure 
8-A) shows that approximately 88% of the EC are in the negative PC1 axis, whereas 80% 
of the control samples are in the positive PC1.  
According to the Loadings (variables plot; Figure 8-B) the EC group is 
characterized by higher sTn and sLe
a
 and to some extent Tn, as previously observed in 
Figure 8- B. Conversely, the control group is discriminated based on higher levels of T and 
sLe
x
. The PC2 axis does not allow discriminating more groups with the available 
information. Moreover, it was not possible to discriminate the tumors in relation to their 
clinic-pathological classification using PCA, thus in accordance with the results from the 
Chi-square test. Altogether, this serological analysis suggested that a combination of Tn, 
sTn and sLe
a
 could be used to better discriminate between EC and the control group. All 
together, this data demonstrates that, in addition to the sTn and sLe
a
 antigens, the Tn can 
also be used to characterize EC patients using serum 
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Figure 8. Principal components analysis (PCA) for the expression of tumor-associated 
glycans Tn, sTn, T, sLe
a
, and sLe
x 
in serum for controls (n=10) and EC (n=16). A) 
Scores plot for PC1 vs PC2 accounting for 67.8% of sample variance. Samples marked red 
correspond to EC (SCC, AC, and those without available clinical data, termed generally as 
EC); controls were marked blue. EC mainly found in the negative PC1 (87.5%) whereas 
the controls are in the positive PC1 (80%). However, it was not possible to interpret the 
grouping presented by PC2 th the available information about the samples. B) Loading plot 
showing that PC1 negative sample was characterized by elevated Tn, sTn, and sLe
a
 and 
PC1 positive by elevated sLe
x
 and T  
Given the tumor-associated nature of the Tn, sTn, and sLea antigens, ROC curves 
were applied to determine their sensitivity and specificity as serum biomarkers (Table 5) 
antigens. The sTn antigen presented the highest sensibility (81.3%) and the best combined 
specificity (80.0%). On the other hand, sLe
a
 showed 100% specificity, but only 50% 
sensibility. Based on the insights from PCA (Figure 8), showing that sTn and sLe
a
 and, to 
some extent, the Tn antigens are good discriminators of EC, the sensibility and specificity 
of these antigens was tested in combination (Table 5). As shown in Table 5, the 
combination of sTn and Tn retrieved the best results, with 93.8% sensibility and 100% 
sensitivity. The introduction of sLe
a
 in this array did not improve the quality of these 
indicators. 
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Table 5. Sensibility and specificity of Tn, sTn and sLe
a
 individually and in 
combination. 
 
 
Antigen 
 
 
Sensibility (%) 
 
Specificity (%) 
   
Tn 68.8 80.0 
   
sTn 81.3 80.0 
   
sLe
a
 50.0 100 
   
Array of antigens 
   
sLe
a
 + sTn 81.3 100 
   
sLe
a  
+ Tn 75.0 100 
   
sTn + Tn 93.8 100 
   
Sle
a
 + Tn + sTn 93.8 100 
    
 
4.1.2. Screening of tumor-associated glycans in EC 
Seven FFPE tissues were characterized in relation to Tn, sTn, T, sLe
a
, and sLe
x
 
expression by immunohistochemistry (IHC). The mono-sialylated forms of the T antigens, 
s6T and s3T were also included, even though they were not evaluated in serum. Both the T 
and sialylated T antigens were evaluated for the first time in EC. The FFPE tissues 
included the tumor and adjacent reactive mucosa.  
The percentage of expression of the studied antigens in EC tumors and adjacent 
mucosa has been comprehensively resumed in Table 6. All antigens were detected in the 
cell membrane and also in the cytoplasm, even though in lower extent. They could also be 
observed in secreted mucins in adenocarcinomas. As shown in Table 6, all cases were 
negative for the Tn antigen, whereas the sTn, T, and sLe
x
 antigens presented lower 
expressions in comparison to s3T, s6T, and sLe
a
. The sTn antigen was detected in 7/8 
cases, diffusely expressed throughout the tumor (Figure 9B). It was also found in the basal 
luminal cells of the adjacent epithelia (Figure 9A). The T antigen was only found in 
mucins in adenocarcinomas (Figure 9D) and in the gastric metaplasia (Figure 9C). The 
sLe
x
 antigens presented an expression pattern similar to sTn, with the exception that it was 
not present in the adjacent mucosa (Figure 9- E). Still, it was extensively expressed in the 
stromal tissues (Figure 9- F).  
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Regarding the sialylated forms of the T antigens, s3T was detected after digestion 
of the FFPE tissues with a -(2,3)neuraminidase to yield the T antigen, followed by 
detection with mouse monoclonal antibody 3C9. By comparison with the expression of the 
T antigen, 3 SCC and the gastric metaplasia were considered positive for s3T (Table 6 
Figure 9I). Like the T antigen, s3T was not found in the adjacent mucosa. The s6T antigen 
was detected after digestion of the FFPE tissues with a b-(1,3)galactosidase to yield the 
sTn antigen and then detected using mouse monoclonal antibody TKH2. By comparison 
with the expression of the sTn antigen, all cases and adjacent mucosa were considered 
positive for s6T (Table 6, Figure 9J). Based on these observations, s6T was considered to 
be the most expressed of the two sialylated forms of the T antigen.  
Table 6. Expression of tumor-associated carbohydrate antigens Tn, sTn, T, T+s3T, 
sTn+s6T, sLe
a
, and sLe
x
 by immunohistochemistry.  
  
 
Tn 
 
 
sTn 
 
T 
 
T+s3T
1
 
 
sTn+s6T
2
 
 
sLe
a
 
 
sLe
x
 
 
 
AM 
 
 
T 
 
AM 
 
T 
 
AM 
 
T 
 
AM 
 
T 
 
AM 
 
T 
 
AM 
 
T 
 
AM 
 
T 
               
ESSC               
               
Case 1 - - + + - - - - + ++++ +++ ++++ - + 
               
Case 2 - - + + - - - - ++ +++ +++ ++++ - + 
               
Case 3
3
               
SCC - - + + - - - + ++++ + +++ ++++ - + 
Metaplasia x - x ++ x + x ++++ x ++++ x - x + 
               
Case 4 - - + + - - - + ++ +++ ++ +++ - + 
               
Case 5 - - + + - + - +       
               
AC               
               
Case 6 - - - - - + - + + ++++ ++++ ++ - - 
               
Case 7 - - + + - + - + + ++ ++ +++ - + 
               
Antigen Expression: “x”: not present; “-“: negative; “+”: >5-20%; “++”: >20-35%; “+++”: >35-50%; ++++: 
>50% (extensive); “AM” stands for tumor adjacent mucosa which was in all cases considered already as 
reactive mucosa, showing pronounced histological alterations. “T” stands for tumor; 1Determined using 
mouse monoclonal antibody 3C9 anti-T antigen after digestion with a b-(1,3)galactosidase; 2Determined 
using mouse monoclonal antibody TKH2 anti-sTn antigen after digested with a -(2,3)neuraminidase; 3This 
case presents a SCC and gastric metaplasia, as a result, the tumor and the EC precursor lesion were evaluated 
separately.  
The sLe
a
 antigen was highly expressed in all tumors and adjacent mucosa, with the 
exception of the gastric metaplasia. Moreover, it was always more expressed in the tumors 
than in the adjacent mucosa (Figure 9H).  
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Figure 9. Expression of tumor-associated carbohydrate antigens Tn, sTn, T, T+s3T, 
sTn+s6T, sLe
a
, and sLe
x
 by immunohistochemistry. Expression of the A) stn in a SCC 
adjacent mucosa; B) sTn in a SCC; C) T antigen in gastric metaplasia; D) T antigen in a 
AC; E) sLe
x
 antigen in a SCC adjacent mucosa; F) sLe
x
 antigen in SCC; G) sLe
a
 antigen in 
a SCC adjacent mucosa; H) sLe
a
 antigen in a SCC. I) SCC 1) negative for the T antigen 
and 2) positive for s3T; confirms the expression of the s3T antigens. J) SCC 1) negative for 
the sTn antigen and 2) positive for s6T antigen; confirms the expression of the s6T 
antigens 
 
In resume, it has been highlighted that studied EC tissues extensively express sLe
a
 
and do not express the Tn antigen. Based on the data provided in Table 6, the percentage of 
expression of the antigens in FFPE tissues can be ordered as follows: 
sLe
a
>s6T>sTn>sLe
x
>s3T>T.  
4.1.3. Correlations between serum and tissue expression of tumor-associated antigens  
 The graphical matrix in Figure 10 highlights correlations between the serological 
levels of tumor-associated glycans (Figure 8) and the expression in the corresponding 
tissues (Table 6). Based on the Tn, sTn, and sLe
a
 serum levels and the cutoffs determined 
sTn sLexT
A
B
C
D
E
F
sLea
G
H
sTn -s3T +T - s6T +
I-1 I-2 J-1 J-2
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using ROC curves (data not shown), the cases were classified has EC negative or positive. 
These cases were then matched against the results from immunohistochemistry. For the Tn 
antigen, 4 cases were considered positive by serology but the antigen was not detected in 
the tissue in any of the cases. Thus, no correlation was found between these events. 
Conversely, matched results were found in 5 out of the 7 cases expressing sTn, 
highlighting a significant correlation between the serum and EC tissues, regardless of the 
low levels of sTn expression presented by EC tissue (Table 6). The sLe
a
 antigen presented 
a matched positivity only in 2 out of 7 cases, despite the high levels of sLe
a
 expression 
presented by all the tissues (Figure 9H, Table 6). 
Overall, this data suggests the lack of correlation between the expression for these 
glycosylated tumor-associated antigens in the serum and corresponding EC tumor tissue.  
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Figure 10. Graphical matrix highlighting the expression of EC associated glycans Tn, 
sTn, and sLea in serum and in the corresponding EC tissues. The sera were classified 
as positive or negative based on cutoffs given by ROC analysis (data not shown). 
4.2. Discussion 
This chapter described that the serum of a group of EC patients presented elevated 
levels of Tn, sTn and sLe
a
 antigens, when compared to a group of individuals, with 
matched in age and sex, and without any known oncological disease. It was also observed 
that the Tn and sTn could be used in combination to better discriminate the two groups. In 
accordance with these findings, three studies have previously reported high levels of sTn in 
the serum of EC patients using ELISA [23]. Elevated sLe
a
 were also detected in 50% of the 
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patients, which is in accordance with the values reported by Türkyilmaz et al. for a series 
of 50 EC using ELISA [77]. However, two other studies, comprehending a total of 335 
SCC have reported significantly lower sLe
a
 expressions (approximately 20%) for EC [20, 
78]; conversely one study involving 33 AC, reported 42% of sLe
a
 positive cases [20]. 
Altogether, this data suggests that elevated levels of sLe
a
 in the serum may be a 
characteristic feature of AC. Due to the low number of cases in our series, it was not 
possible to confirm these observations. Still, all serological studies conducted so far, 
consensually describe elevated sTn and sLe
a
 antigens in serum with EC. Our findings 
reinforce these observations and add that the Tn antigen, here evaluated for the first time, 
is also elevated in the sera of EC patients. More studied are now needed, using larger 
series, to determine the biomarker value of these antigens in the context of EC. Of note, 
both the T and sLe
x
 antigens that are normally elevated in the serum of cancer patients 
were significantly decreased in the sera of EC patients when compared to the controls. 
More studies should be conducted to determine whether this is a particular feature of the 
studied EC population. This suggests that Tn, sTn and T expression may stem from the 
same protein(s), and suggests that EC cells may be producing or inducing the production of 
low molecular weight glycans by other cells. On the other hand, the sLe
a
 is the type 1 chain 
(structure) positional isomer of sLe
x
. A possible shift from type 2 to type 1 structures may 
be occurring in EC serum-associated glycoproteins. However, further studies are needed to 
address these observations 
Additionally, tumor-associated antigens were evaluated in some of the EC tissues, 
in an attempt to highlight correlations with the serological observations. All the evaluated 
EC tumor tissue presented high levels sLe
a
 expression (>35% of tumor), irrespectively of 
the histopathological classification of the tumor. The sLe
a
 antigen was also observed in the 
tumor adjacent mucosa, however in lower extent than in the corresponding tumor. 
According to Ikeda et al., sLe
a
 is not expressed in the “healthy” esophageal epithelia, thus 
demonstrating is tumor-associated nature [74], but it was observed in both EC precursor 
lesions and tumors [4], thus in accordance with the results presented in this work. 
However, significant inter-study variability was found regarding the percentage of positive 
cases (4-52%), which can either result from the use of different antibodies or be associated 
with sampling. The sTn and sLe
x
 antigens were also detected in the majority of the EC 
tumors, thus also in accordance with previous reports [22, 31, 75]. However, while sTn 
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could also be found in the adjacent mucosa, sLe
x
 expression was restricted to the tumor. 
Similar to what was observed for sLe
a, the sTn antigen has also absent from the “healthy” 
esophageal epithelia [22], but it can be found in EC precursor lesions [31]. The T antigen 
and their monosialylated forms, s3T and s6T. The T antigen were also studied. The T 
antigen mostly observed in mucins in AC while the s3T could also be found in SCC; 
however both presented low levels of expression (<10%, data not shown in Table 6). 
However, the s6T antigen was highly expressed in EC (>35% of the tumor) and, in less 
extent in the corresponding adjacent mucosa. Even though the s6T antigen was not 
evaluated in the serum, its elevated expression in the tumors reinforces the need for further 
studies. Contrasting with the above described antigens and also with previous findings [31, 
74, 75], the T antigen could not detected in any of the studied EC tissues. The low 
abundance of T antigens in this tissues compared with the high expression of s6T denotes 
an overexpression of ST6GALNAc.II enzyme in this tissues 
However, when the data from immunohistochemistry was matched with the levels 
of Tn, sTn, and sLe
a
 in serum, some lack of correlation discrepancies could be observed. 
The most salient was the lack of detection of the Tn antigen in tissues that contrasted with 
the elevated levels of expression in the sera of EC patients. Another contrasting feature 
was the lack of correlation between the elevated expression of sLe
a
 in the tumors and the 
corresponding sera. Such correlations were only evident for the sTn antigens. However, 
one is led to discuss, that the low levels of sTn in the tissues (generally <10% of the tumor, 
data not shown in Table 6) may not account for the high lvels of sTn found in serum. 
Tumor proteins are present in only minute quantities in complex physiological milieus 
such as serum, which is composed of thousands of proteins spanning a dynamic range of 
10 orders of magnitude. The distribution of these proteins is dominated by a few highly 
abundant proteins, accounting for 99% of the total proteome [103]. Therefore, without 
prior enrichment steps, it unlikely that the glycosylation of tumor proteins could be 
responsible by the observed differences between the EC and control groups, even using 
highly sensitive analytical methods such as western blotting with chemoluminescent 
detection. These differences are most likely a result from alterations in the glycosylation 
pattern of more abundant serum glycoprotein, denoting tumor-driven systemic alterations. 
Nevertheless, glycoproteins carrying tumor-associated glycans can also be found in 
circulation [30]. In line with these observations, Shao et al. reported elevated levels of sLe
a
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in IL6, IL10, and serum amyloid A (SAA) and sTn in IL10 and von Willebrand factor 
protein in the serum of EC patients [79]. Of note, sLe
a
 was also observed in MUC1 and 
sTn in cathepsin and gelsolin that are indeed proteins secreted by tumor cells [79].  
Further studies should be conducted to determine the events leading to changes in 
the glycoprofile of the sera of EC patients. The identification of protein carriers may also 
bring more insights to this matter and provide novel, more specific and sensitive, 
biomarkers. Also, studies should be conducted in larger series of patients to confirm these 
findings. 
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5. Humoral responses against EC proteins expressing sLe
a 
 
sLe
a
 is expressed in cancer cells, mimicking their normal expression on blood cells 
(monocytes and neutrophils) and consequently their potential for migration through 
binding to endothelial cell selectins [30, 48]. Thus, sLea is explored in serological tests as a 
marker of poor prognosis (CA19-9 test) for several cancers [20].  
Chapter IV described that all studied EC tissue presented high expression of sLe
a
. 
However, despite showing a specificity of 100%, sLe
a
 was only elevated, by comparison 
with the control group, in 50% of the studied EC patients. Moreover, data suggested a lack 
of correlation between the sLe
a
 levels in serum and the high expression in the tissues. 
Thus, given its contribution to malignancy, the development of highly sensitive and 
specific detection non-invasive tests to target sLe
a
 is a critical matter.  
Recent studies are demonstrating that tumor-associated proteins carrying altered 
glycosylated domains are responsible for exerting strong humoral responses [86, 88, 90]. 
IgGs are regarded as the next generation of tumor biomarkers, since they are highly 
sensible and specific, resistant to proteolysis, and capable of amplifying subtle molecular 
changes in the tumors [39, 83]. Based on these observations, chapter V describes an 
explorative study directed to identify humoral responses to EC glycoproteins carrying sLe
a
.  
The generated information is regarded of major importance to direct studies envisaging the 
non-invasive diagnoses of EC. Moreover it will allow pinpointing immunogenic 
glycoproteins with putative therapeutic value.  
5.1. Results 
5.1.1. IgG expression in serum 
 
All sera were first characterized in relation to their IgG content. As shown by 
Figure 11A the IgG levels are elevated in the EC group when compared to the controls; 
however this difference is not statistically significant. However, when the IgG subtypes 
were analyzed individually by slot blotting (Figure 11B-1), it was observed that IgG1 was 
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significantly elevated in the EC group (Figure 11B-2). However, no differences were found 
between the two groups for the other subtypes of IgGs.  
 
Figure 11. Correlations between IgG and sLe
a
 levels in serum. A-1) shows the levels of 
IgG in the serum expressed in terms of g/L of serum; 2) shows the levels of IgG in 
serum expressed in terms of g/g of serum proteins. The IgG were elevated in the sera of 
the EC patients in comparison to the controls, however this difference is not statistically 
significant. B-1) Slotblot showing an elevated expression of IgG1 in the EC in comparison 
to the controls; 2) Expression of IgG subclasses (IgG1, IgG2, IgG3, IgG4) in the serum. 
IgG1 was found significantly elevated in the serum of EC patients (p<0.001) 
Serum IgG concentrations were matched against the amounts of sLe
a
 to mine 
possible associations between both events. As shown in Figure 12-A, for 50% of the 
controls and 69% of the EC a linear tendency was observed (R
2
 = 0.7011); when plotted 
separately, a similar behavior was also observed (Figure 12- B and 12- C). Nevertheless, 
this data shows that IgG and sLe
a
 were more correlated in EC than in the controls. 
Likewise, correlations of sLe
a
 that showed higher differences between the control and EC 
groups, were studied. In this case, no linear behaviors were found among the controls 
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(Figure 12-D and 12- E), either in combination with the EC samples (Figure 12 D) or when 
plotted separately (Figure 12 E); however, approximately 63% of EC cases presented a 
significant linear correlation between the expression of sLe
a
 and IgG1 (R
2
 = 0.9804; Figure 
12- F).   
 
Figure 12. Figure 12. Scatterplot matrixes highlighting relationshiphs between sLea 
and IgG/IgG1 in serum A) IgG vs sLe
a
 showing a correlation with an R
2
 = 0.7011 for 
50% of the controls and 69% of EC; B) IgG vs sLe
a
 showing a correlation with an R
2
 = 
0.8286 for 50% of the controls; C) IgG vs sLe
a 
showing a correlation with an R2 = 0.7656 
for 69% of EC; D) IgG1 vs sLe
a
 showing a correlation with an R2 = 0.89 for 30% of the 
controls and 63% of EC; E) IgG1 vs sLe
a
 showing no correlation for the controls; F) IgG1 
vs sLe
a
 showing a correlation with an R2 = 0.9804 for 63% of EC. This data shows that the 
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expression of sLe
a
 is correlated with the expression of IgG, and particularly with IgG1. 
These correlations are more significant in the EC than in the control group. 
Altogether, data showed that the expression of sLe
a
 is correlated with the IgG1, and 
that this is an EC-associated event. Moreover, it suggests that IgG, and in particular, IgG1 
in the sera of EC patients, may express sLe
a
. 
 
Figure 13. B) Expression  of sLe
a 
expression in the IgG recovered from whole serum 
by protein G-agarose affinity chromatography, for controls (n=2) and EC (n=4), 
before and after digestion with a α-neuraminidase. The decrease in chemiluminescence 
in the samples after enzymatic treatment confirms the expression of sLe
a
. B) Scatterplot 
matrix highlighting relationships between sLe
a
 expression in the IgG recovered from 
whole serum by protein G-agarose affinity chromatography, and IgG1 levels. The 
observation of a linear correlation with an R
2
 = 0.8096 confirms whole serum observations 
presented in Figure 12-F for the whole serum. 
To determine if serum IgGs expressed sLe
a
, these proteins were first isolated from 
the whole serum by affinity chromatography using protein G-Agarose and then slotblotted 
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for sLe
a
 (Figure 13). As shown in Figure 13A, both the controls (n=2) and EC IgGs (n=4) 
expressed sLe
a
, as confirmed by the absence or decreased signals presented by the 
corresponding samples treated with -neuraminidase. Like observed for the whole serum, 
the isolated IgGs also presented a linear correlation between IgG1 and sLe
a
 (Figure 13B), 
thus reinforcing previous associations between both events. The sLe
a
 levels in the serum of 
EC patients. Still, given its high abundance in serum, IgG are regarded to significantly 
contribute to this effect.  
5.1.2. Humoral responses against EC proteins expressing sLe
a 
 
 The IgG1 levels were found significantly increased in the serum of EC patients as 
well as in the tissues (Figure 14), as shown by immunohistochemistry.  
 
 
Figure 14. Expression of IgG1 in EC tissue 
 
To identify possible IgG1-mediated humoral responses against glycoproteins carrying 
sLe
a
, proteins were extracted from FFPE tissues. Three cases were elected for this 
explorative study: one non-invasive SCC, one non-invasive SCC presenting gastric 
metaplasia, and one invasive SCC. The protein extracts were then incubated with protein 
G-Agarose to remove tumor IgGs and other molecules with affinity for this protein. The 
glycoproteins carrying sLe
a
 were recovered by immunoprecipitation and blotted with a 
mouse anti-sLe
a
 monoclonal antibody. The western blots presented in Figure 14 show 
distinct patterns for each case. The invasive SCC showed more proteins expressing sLe
a 
, 
the majority of which of high molecular weight (>75 kDa). In the non-invasive SCC 
presenting intestinal metaplasia proteins between 50-75 kDa predominate, whereas in the 
SCC case 50-37 kDa predominate. The cross-reactivity of the secondary antibody to mouse 
IgG heavy and light chains that resulted from immunoprecipitation, did not allow 
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determining the presence of sLe
a
 expressing proteins in the bands at 55 and 25 kDa. 
Despite these differences, the cases shared common features. Non-invasive SCC share a 
band at approximately 37 kDa and another above 50 kDa, which were significantly more 
intense in the case not presenting gastric metaplasia. These bands were not found in the 
invasive SCC. The case with gastric metaplasia and the invasive tumor also shared a 
common band below the 75 kDa maker. The invasive SCC presented three additional 
bands above 75 kDa. This demonstrates both the presence of sLe
a
 expressing glycoprotein 
in EC, but also denotes similarities and differences between samples that should be further 
explored.  
 
 
Figure 15. Expression of sLe
a
 in EC proteins isolated by immunoprecipitated with 
mouse anti-sLe
a
 monoclonal antibody, for a non-invasive SSC, a non-invasive SCC 
also with a gastric metaplasia, and an invasive SCC. The lanes more to the righ, for 
each group, show proteins recognized by serum IgG1 recovered from the same 
patients. The blue rectangles highlight common glycoproteins recognized by serum IgG1. 
This reactivity was lost after treatment with a -neuraminidase (data not shown), 
confirming that sLe
a
 is determinant for IgG1 recognition. Figure 15 further highlights, with 
blue arrows, the IgG (heavy and light chains) from the mouse monoclonal antibody using 
for immunoprecipitation. 
 IgGs were then recovered from the serum of the patients and used in the 
identification of IgG1 mediated humoral responses against tumor proteins carrying sLe
a
 
recovered from the corresponding tumors. As shown by Figure 14, the non-invasive SCC 
with intestinal metaplasia and the invasive SCC presented broader spectra of glycoprotein 
recognition, when compared to SCC alone. Also, reactivity was observed in all cases 
against the band at 37 kDa, including the invasive SCC where this glycoprotein was not 
observed with anti-sLe
a 
monoclonal antibody (Figure 14). These observations denote a 
common pattern of IgG1 recognition among EC, irrespectively of their clinic-pathological 
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classification. Other common features between the non-invasive SCC with gastric 
metaplasia and invasive SCC include the recognition of the band at 37 kDa and bellow 150 
kDa. To confirm this is the sLe
a
-dependent recognition, all samples were also incubated 
with a -neuraminidase prior to western blotting. The absence of bands in this blot 
confirmed that sLe
a
 is necessary for IgG1 recognition. 
5.2. Discussion 
This chapter described that IgG1 is significantly increased in the serum of EC 
patients in comparison to the control group. It also demonstrated that these proteins are 
glycosylated with sLe
a
, an event that may account for the significantly high levels of this 
glycan found in the sera of EC patients.  
The Fc fragment is known to bears two N-glycans linked to the conserved Asn-297 
on both heavy chain-derived polypeptides [86]. The N-glycans found on IgG are of the 
complex biantennary type, differing in the levels of the terminal sialic acid, galactose, core 
fucose and bisecting N-acetylglucosamine (GlcNAc) [104, 105]. Additionally, 15–20% of 
serum-derived IgG molecules also have oligosaccharides attached to the Fab region. IgG 
functions rely on the interactions of the Fc region with other proteins [104]. Stimulation of 
the Fc receptor by IgG Fc region results in pronounced functional consequences, including 
antibody-dependent cell mediated cytotoxicity (ADCC), antibody-dependent cellular 
phagocytosis and release of inflammation-associated mediator molecules [106]. The 
interaction of the Fc region with complement components results in complement-
dependent cytotoxicity [107]. Also, different stimuli received by B cells during their 
activation and differentiation can modulate the Fc-linked glycosylation of secreted IgG1 
without affecting the general cellular glycosylation machinery [104]. Also, the 
glycosylation profiles of IgG are tightly regulated by physiological and pathological 
determinants in an antigen-specific manner [105]. In healthy individuals, IgG glycosylation 
features are reflected in age, gender and pregnancy [86]. Thus, alterations in the 
glycosylation pattern of IgGs have been observed in several human malignancies, namely 
multiple myeloma patients [108], gastric [109], prostate [110], thyroid [111] cancer and 
found to be correlated with specific clinic-pathological features. However, to our 
knowledge, the cancer-associated expression of IgG1 carrying sLe
a
 is being observed for 
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the first time. Given the high correlation of this event with malignant transformation, this 
observation may allow to improve the sensitivity and specificity of the CA19-9 test. A 
deeper understanding of the IgG1 glycosylation patterns associated may further improve 
the diagnostic of EC.  
Along with the over-expression of IgG1, it was also observed that this particular 
IgG subclass could recognize proteins carrying sLe
a
 in tumors, in a sLe
a
-dependent 
manner. Even though this was a preliminary study involving only 3 SCC of different 
histopathological natures, common patterns of IgG1 recognition between the cases. 
However, tumor-specific immunogenic proteins were also observed. Reports of 
autoantibodies to glycosylated proteins expressing the Tn, sTn, and sLe
x
 have been 
presented [37, 68, 101]. Moreover, it was demonstrated that humoral responses are 
dependent on the particular peptide domain exhibiting the glycosylation [68]. To our 
knowledge this is the first study concerning sLea, despite its clinical importance. 
Additionally, this study highlighted both differences and similarities in the types of 
proteins expressing sLe
a
 from tumor to tumor. Further studies should now be conducted to 
determine the identity of these proteins, their biomarker value as well as the biomarker 
value of the IgGs generated against them. This may not only allow improving the diagnosis 
of EC, but also provide immunogenic molecules that can be explored in therapeutics.  
These observations are of major relevance, since sLe
a
 is widely expressed not only 
in EC, but also on epithelial tumors of the gastrointestinal tract [48], breast [44] and on 
small-cell lung cancers [34] and is considered a key event in invasion and metastasis of 
many tumors [112]. 
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6. Conclusions 
 
The first part of this work aimed to identify glycosylation patterns in serum 
associated with EC. It was concluded that the levels of sTn, and sLe
a
 antigens and, to some 
extent Tn, were significantly increased in the serum of the patients in comparison to a 
control group, matched in gender and age, without knowing malignant diseases. Moreover, 
it was demonstrated that the combination of the Tn and sTn antigens could be used to 
better discriminate the EC patients. Still, the expression of these antigens in the 
corresponding EC tissues, estimated by immunohistochemistry, showed a lack of 
correlation with the observations made in serum. Data suggests that glycosylation patterns 
of serum are mostly influenced by proteins that are not directly secreted or released from 
tumor cells, even though their contribution cannot be excluded.  
The second part of the work aimed to identify humoral responses against proteins 
carrying the sLe
a
, a glycosylated biomarker associated with increased potential of cellular 
migration and metastasis. The analysis of the IgG profile of the samples showed increased 
expression of IgG subclasse 1 (IgG1) in EC patients. De novo produced IgG1 were found 
to carry sLe
a
, accounting for the increase in the levels of this glycan in the serum of EC 
patients. Even though the biological events underlying these observations remain to be 
clarified, this may allow improved the sensibility and specificity of the serological test for 
sLe
a
 (CA19-9 test). Using a combination of immunoprecipiations and western blotting 
techniques it was further demonstrated, for the first time, that tumor proteins carrying sLe
a
 
could elicit IgG1 production. Furthermore, experiments using desialylated proteins 
confirmed that the expression of sLe
a
 expression was determined for IgG1 recognition.  
These observations and the future identification of the immunogenic proteins 
carrying sLe
a
 will allow determining the clinical value of this explorative work and guiding 
the development of autoantibody-based serological tests.  
Altogether, important insights have been provided to guide the development of non-
invasive serological tests for the detection of EC. 
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7. Future works and perspectives 
 
This work as provided important insights about the serum glycosylation patterns 
associated with EC. Future studies should be conducted to validate these observations in a 
series involving a higher number of patients, of variable ages and genders, encompassing 
the different clinic-pathological features. EC precursor lesions should be included in this 
dataset. A higher number of controls should also be studied. These should include also 
include controls with inflammatory disease, diabetes, among other pathologies, to isolate 
cancer-associated patterns. Proteomic studies will also allow identifying the proteins 
showing abnormal glycosylation and, consequently, improving the accuracy of the 
serological tests based on altered glycosylation. Furthermore, it will bring insights on the 
biologic events underlying the alteration of serum glycosylation patterns.  
 Regarding the humoral response against sLe
a
 in EC, it will be necessary to identify 
the protein carriers for this glycan and their correlation with clinic-pathological status. 
Then it will be necessary to determine the levels of autoantibodies in serum against the 
identified protein(s) to access their biomarker potential. The generated information may 
allow improving the accuracy of the CA19-9 in EC. 
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